Glenmark Pharmaceuticals Limited has introduced the first triple-drug fixed-dose combination (FDC) in India, Zita®DM, which includes Teneligliptin (20mg), Dapagliflozin (10mg), and Metformin SR (500mg/1000mg). This medication, taken daily under prescription, aims to improve glycemic control in Type 2 diabetes patients.
Glenmark’s Zita® portfolio of medicines has been benefiting around 1.75 million Type 2 diabetic patients annually, in India. With the launch of Zita® DM, Zita® the most comprehensive glipt in range now holds promise of helping Type 2 diabetic patients at every stage of their treatment. On the occasion of the launch, Alok Malik, President& Business Head ‐ India Formulations, Glenmark Pharma stated, “With this robust profile, we are positive Zita® DM will facilitate patient adherence to chronic diabetes treatments.”
Zita® DM improves glycemic control in adult patients with high HbA1c, uncontrolled diabetes, and those requiring Teneligliptin and Dapagliflozin as separate drugs. Its cost is INR 14 per tablet per day, lowering the daily therapy cost by 30%, making it affordable.
